1. Home
  2. /
  3. Investments
  4. /
  5. Physioassist

Physioassist

PhysioAssist has developed a unique expertise in bronchial mucus analysis and clearance. Their model of digital simulation allowed for a detailed analysis of the impact of vibrational signals on human mucus in the distant airways of the bronchi. The stagnation of mucus in these areas is often considered to be a root cause of pulmonary infections. Patients with obstructive pathologies have to clear their airways on a daily basis.

PhysioAssist’s lead product, Simeox™, delivers a simple solution to clear airways efficiently, particularly suited for COPD and Cystic Fibrosis patients. It is currently commercialized in France and some countries within Western Europe.

A session of treatment with Simeox™ typically lasts for 10 to 20 minutes and is supervised by a healthcare professional, and can be provided at home, to improve quality of life and patient compliance.

Team

Venture Capital

Status

Divested

Geography

Europe

Financing Round

Financing round - Series B

Segment

Medical Devices

Entry Date

2017

Key Figures

Divested

Status

2012

Creation Date

15

Number of Employees

2017

Investment Date

Mérieux Participations 2

Fund Name

Key Contacts

Related companies